M.D. Anderson Cancer Center: Cholangiocarcinoma trials

The registry lists 11 Cholangiocarcinoma studies with M.D. Anderson Cancer Center as lead sponsor. 2 are open to participants now and 3 have results posted.

Phase 1 6Phase 2 4No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic CholangiocarcinomaRecruitingNCT05967182Phase 2
• Molecular Epidemiology of Biliary Tree CancersRecruitingNCT05179486
• Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by SurgeryCompletedNCT02520141Phase 2Results posted
• Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary CancersCompletedNCT02392637Phase 2Results posted
• Oxaliplatin and Capecitabine in Patients With Unresectable CholangiocarcinomaCompletedNCT00338988Phase 2Results posted
• Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/AmplificationWithdrawnNCT05510427Phase 1
• Hypofractionated Radiation Therapy and Bintrafusp Alfa for the Treatment of Advanced Intrahepatic CholangiocarcinomaActive, not recruitingNCT04708067Phase 1
• CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal TumorsTerminatedNCT02757391Phase 1
• Radiation Therapy in Treating Patients With Hepatocellular Carcinoma, Cholangiocarcinoma, or Liver Metastasis Who Have Impaired Liver FunctionTerminatedNCT02626312Phase 1
• 18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or TransplantActive, not recruitingNCT02379377Phase 1
• Proton Therapy and Bevacizumab for Primary Liver TumorsTerminatedNCT00426829Phase 1